Search Within

Shari Goldfarb

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Breast Medicine Service (6)
  2. Department of Medicine (6)
  3. Department of Pathology and Laboratory Medicine (6)
  4. Epidemiology and Biostatistics (6)
  5. Health Outcomes Research Group (6)
  6. Population Sciences Research Program (6)

More Groups

People
  1. Gabriella D'Andrea-Carlino (4)
  2. Sarat Chandarlapaty (4)
  3. Sujata Patil (4)
  4. Anne Covey (3)
  5. Betty Ann Caravella (3)
  6. Clifford Hudis (3)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2016 (1)
  4. 2015 (2)
  5. 2014 (1)
Publications
  1. Cancer Research (2)
  2. Journal of Clinical Oncology (2)
  3. Breast Cancer Research and Treatment (1)
  4. Journal of Nuclear Medicine (1)
Publishers
  1. American Association for Cancer Research (2)
  2. American Society of Clinical Oncology (2)
  3. Society of Nuclear Medicine (1)
  4. Springer (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment
    Journal Article

    Hogan, M. P.; Horvat, J. V.; Ross, D. S.; Sevilimedu, V.; Jochelson, M. S.; Kirstein, L. J.; Goldfarb, S. B.; Comstock, C. E.; Sung, J. S.
    Breast Cancer Research and Treatment (2023)

    Fulltext@MSK | Save
  • Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer
    Meeting Abstract

    Gucalp, A.; Boyle, L. A.; Alano, T.; Arumov, A.; Gounder, M. M.; Patil, S.; Feigin, K.; Edelweiss, M.; D'Andrea, G.; Bromberg, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT
    Journal Article

    Ulaner, G. A.; Hyman, D. M.; Ross, D. S.; Corben, A.; Chandarlapaty, S.; Goldfarb, S.; McArthur, H.; Erinjeri, J. P.; Solomon, S. B.; Kolb, H.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save